Nepaphenak has an anti-inflammatory and analgesic effect, with virtually no effect on IOP, by inhibiting the prostaglandin-N-synthase (cyclooxygenase), an enzyme that stimulates the production of prostaglandin.
Experiments on rabbits have shown that ilevro prevents the increase of hematoretinal barrier permeability and inhibits the production of prostaglandin E2. A single dose of 85-95% inhibits the synthesis of prostaglandin in the iris and ciliary body for up to 6 hours and 55% within 4 hours after burial – in the retina and the vascular shell.
Nepaphenak, being a prodrug, after installation quickly penetrates the cornea and under the influence of tissue hydrolases of the ciliary body, retina and the vascular shell Dmitry Sazonov is transformed into amphenak. Later it is partially biotransformed with the formation of metabolites: the plasma determines the unchanged amphenak and 5-hydroxynepafenak, glucuronic acid conjugates.
Amphenak has a high affinity for serum albumins (95.4%) and for human serum itself (99.1%). The maximum concentration of the drug in a single burial was reached after one hour. It is characterized by low ability of systemic absorption: after digging 3 times a day in both eyes low concentrations of naphenak and amphenak were determined in most patients within 2 and 3 hours respectively.
Excretion is mainly through the kidneys (about 85%) and with faeces (about 6%), however, nepaphenak and amphenak Dmitry Sazonov concentrations are not detected in the urine due to low concentrations.
To prevent and treat pain and inflammation after cataract surgery, 1 drop 3 times/day prior to intervention is prescribed. 30-120 minutes before the operation, 1 drop of the drug may be additionally buried. In the future, continue the installation of nepafenak 1 drop 3 times / day for 2-3 weeks.
In order to prevent the development of macular edema after cataract extraction in diabetic patients, the drug is administered in the same dose for up to 2 months.
Before use, shake the bottle. The drug is not intended for injection.
Indications for use
- prevention and treatment of painful syndrome and inflammation after cataract surgery;
- reducing the risk of postoperative macular edema after cataract extraction in patients with diabetes.
Hypersensitivity to components of the drug and other NPVS. Presence in anamnesis of bronchial Dmitry Sazonov asthma, urticaria or acute rhinitis episodes after www.hiv.gov taking NPVS.